Amer Khiyami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amer Khiyami has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Achuthan Sourianarayanane
Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin
1 shared publication - Adam T. Perzynski
Case Western Reserve University
1 shared publication - Aynur Unalp-Arida
Department of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA; and
1 shared publication - Dasarathy
MetroHealth Medical Center
1 shared publication - George Boon-Bee Goh
Department of Gastroenterology and Hepatology Singapore General Hospital Singapore Singapore
1 shared publication - Hawkins
MetroHealth Medical Center
1 shared publication
Latest Publications
- 13 February 2023
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 198 (2) , 369-381
Neighborhood and racial influences on triple negative breast cancer: evidence from Northeast Ohio
Purpose Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) with higher recurrence rates and poorer prognoses and most prevalent among non-Hispanic Black women. Studies of multiple health conditions and care processes suggest that neighborhood socioeconomic position is a key driver of health disparities. We examined roles of patients’ neighborhood-level characteristics and race on prevalence, stage at diagnosis, and mortality among patients diagnosed with BC at a large safety-net healthcare system in Northeast Ohio. Methods We used tumor registry to identify BC cases from 2007 to 2020 and electronic health records and American Community Survey for individual- and area-level factors. We performed multivariable regression analyses to estimate associations between neighborhood-level characteristics, measured by the Area Deprivation Index (ADI), race and comparative TNBC prevalence, stage at diagnosis, and total mortality. Results TNBC was more common among non-Hispanic Black (53.7%) vs. non-Hispanic white patients (46.4%). Race and ADI were individually significant predictors of TNBC prevalence, stage at diagnosis, and total mortality. Race remained significantly associated with TNBC subtype, adjusting for covariates. Accounting for TNBC status, a more disadvantaged neighborhood was significantly associated with a worse stage at diagnosis and higher death rates. Conclusion Our findings suggest that both neighborhood socioeconomic position and race are strongly associated with TNBC vs. other BC subtypes. The burden of TNBC appears to be highest among Black women in the most socioeconomically disadvantaged neighborhoods. Our study suggests a complex interplay of social conditions and biological disease characteristics contributing to racial disparities in BC outcomes.
- 13 February 2023
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 198 (2) , 369-381
Neighborhood and racial influences on triple negative breast cancer: evidence from Northeast Ohio
Purpose Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) with higher recurrence rates and poorer prognoses and most prevalent among non-Hispanic Black women. Studies of multiple health conditions and care processes suggest that neighborhood socioeconomic position is a key driver of health disparities. We examined roles of patients’ neighborhood-level characteristics and race on prevalence, stage at diagnosis, and mortality among patients diagnosed with BC at a large safety-net healthcare system in Northeast Ohio. Methods We used tumor registry to identify BC cases from 2007 to 2020 and electronic health records and American Community Survey for individual- and area-level factors. We performed multivariable regression analyses to estimate associations between neighborhood-level characteristics, measured by the Area Deprivation Index (ADI), race and comparative TNBC prevalence, stage at diagnosis, and total mortality. Results TNBC was more common among non-Hispanic Black (53.7%) vs. non-Hispanic white patients (46.4%). Race and ADI were individually significant predictors of TNBC prevalence, stage at diagnosis, and total mortality. Race remained significantly associated with TNBC subtype, adjusting for covariates. Accounting for TNBC status, a more disadvantaged neighborhood was significantly associated with a worse stage at diagnosis and higher death rates. Conclusion Our findings suggest that both neighborhood socioeconomic position and race are strongly associated with TNBC vs. other BC subtypes. The burden of TNBC appears to be highest among Black women in the most socioeconomically disadvantaged neighborhoods. Our study suggests a complex interplay of social conditions and biological disease characteristics contributing to racial disparities in BC outcomes.
- Open Access
- 12 May 2017
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 11 (1) , 1-6
Concordant clear cell “mesonephric” carcinoma of the bladder and lung adenocarcinoma with clear cell features – multiple primaries versus metastatic neoplasms: a case report
Clear cell carcinoma of the bladder is a rare variant of urinary bladder adenocarcinoma. We report a case of a patient with clear cell carcinoma of the bladder and a concordant right upper lobe pulmonary adenocarcinoma with clear cell features, and we address the role of immunohistochemistry and cytogenetic analysis in distinguishing the two primary malignancies. Our patient was a 59-year-old African American woman who presented with hematuria. Her past medical history included invasive mammary carcinoma and end-stage renal disease treated with hemodialysis. A computed tomographic urogram revealed a 3-cm polypoid bladder mass. A follow-up chest computed tomographic scan revealed a 1-cm right upper lobe nodule. The patient underwent transurethral biopsy and subsequent radical cystectomy, as well as a transthoracic core needle biopsy of the lung nodule. Histologically, the bladder tumor consisted of flat, cuboidal to columnar cells with clear or eosinophilic cytoplasm and a hobnail appearance, organized in tubulocystic and papillary patterns. The neoplastic cells were diffusely positive for α-methylacyl-coenzyme A racemase, cancer antigen 125, and cytokeratin 7; focally positive for cytokeratin 20, P53, and carcinoembryonic antigen; and negative for thyroid transcription factor 1. The lung tumor demonstrated a glandular architecture with mucin production (positive for mucin with mucicarmine and periodic acid-Schiff with diastase stain). The neoplastic cells were diffusely positive for cytokeratin 7, napsin A, and thyroid transcription factor 1, and they were negative for cytokeratin 20 and cancer antigen 125. Genetic testing of the pulmonary neoplasm demonstrated ARID2 genomic alterations. The presence of clear cell features in both neoplasms raised the possibility of lung metastasis from the primary bladder tumor. However, the glandular architecture of the lung neoplasm along with its distinctive immunohistochemical and genetic profiles confirmed the presence of two separate primaries.
- 12 May 2017
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 11 (1) , 1-6
Open AccessConcordant clear cell “mesonephric” carcinoma of the bladder and lung adenocarcinoma with clear cell features – multiple primaries versus metastatic neoplasms: a case report
Clear cell carcinoma of the bladder is a rare variant of urinary bladder adenocarcinoma. We report a case of a patient with clear cell carcinoma of the bladder and a concordant right upper lobe pulmonary adenocarcinoma with clear cell features, and we address the role of immunohistochemistry and cytogenetic analysis in distinguishing the two primary malignancies. Our patient was a 59-year-old African American woman who presented with hematuria. Her past medical history included invasive mammary carcinoma and end-stage renal disease treated with hemodialysis. A computed tomographic urogram revealed a 3-cm polypoid bladder mass. A follow-up chest computed tomographic scan revealed a 1-cm right upper lobe nodule. The patient underwent transurethral biopsy and subsequent radical cystectomy, as well as a transthoracic core needle biopsy of the lung nodule. Histologically, the bladder tumor consisted of flat, cuboidal to columnar cells with clear or eosinophilic cytoplasm and a hobnail appearance, organized in tubulocystic and papillary patterns. The neoplastic cells were diffusely positive for α-methylacyl-coenzyme A racemase, cancer antigen 125, and cytokeratin 7; focally positive for cytokeratin 20, P53, and carcinoembryonic antigen; and negative for thyroid transcription factor 1. The lung tumor demonstrated a glandular architecture with mucin production (positive for mucin with mucicarmine and periodic acid-Schiff with diastase stain). The neoplastic cells were diffusely positive for cytokeratin 7, napsin A, and thyroid transcription factor 1, and they were negative for cytokeratin 20 and cancer antigen 125. Genetic testing of the pulmonary neoplasm demonstrated ARID2 genomic alterations. The presence of clear cell features in both neoplasms raised the possibility of lung metastasis from the primary bladder tumor. However, the glandular architecture of the lung neoplasm along with its distinctive immunohistochemical and genetic profiles confirmed the presence of two separate primaries.
- 24 February 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (6) , 1825-1831
Age Impacts Ability of Aspartate–Alanine Aminotransferase Ratio to Predict Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
While histological differences have been reported between pediatric and adult nonalcoholic fatty liver disease (NAFLD), potential age-related changes in serum transaminases and liver histology remain largely unexplored. Our study sought to investigate the clinical and histological characteristics of NAFLD across age. This was a prospective cross-sectional study of 502 biopsy-proven NAFLD patients. Clinical data were evaluated and compared among different age groups; group A (ages 18–44), B (ages 45–64), and C (≥ages 65). 34.9, 56.0, and 9.1 % of the cohort were distributed among group A, B, and C, respectively. While the prevalence of nonalcoholic steatohepatitis (NASH) was comparable across age groups, the prevalence of advanced fibrosis increased with age (p = 0.000). Although the mean ALT progressively decreased with age; 87, 64, 56 U/L in group A, B, and C, respectively (p = 0.000), there was no difference in mean AST (p = 0.939) across age. The AST:ALT ratio (AAR) progressively increased from 0.7, 0.9, and 1.1 in group A, B, and C, respectively (p = 0.000). In group C, an AAR ≥1 was found in 74 and 40 % of patients with and without advanced fibrosis. With advancing age, ALT levels progressively declined while AST levels remained stable, leading to a higher AAR. Although higher AAR is often used as a surrogate measure of advanced fibrosis, advancing age can also contribute to increased AAR. In fact, an AAR ≥1 was found in significant number of elderly patients without advanced fibrosis. Consequently, an increased AAR may be a function of decreasing ALT with age in addition to progressive fibrosis.
- 24 February 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (6) , 1825-1831
Age Impacts Ability of Aspartate–Alanine Aminotransferase Ratio to Predict Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
While histological differences have been reported between pediatric and adult nonalcoholic fatty liver disease (NAFLD), potential age-related changes in serum transaminases and liver histology remain largely unexplored. Our study sought to investigate the clinical and histological characteristics of NAFLD across age. This was a prospective cross-sectional study of 502 biopsy-proven NAFLD patients. Clinical data were evaluated and compared among different age groups; group A (ages 18–44), B (ages 45–64), and C (≥ages 65). 34.9, 56.0, and 9.1 % of the cohort were distributed among group A, B, and C, respectively. While the prevalence of nonalcoholic steatohepatitis (NASH) was comparable across age groups, the prevalence of advanced fibrosis increased with age (p = 0.000). Although the mean ALT progressively decreased with age; 87, 64, 56 U/L in group A, B, and C, respectively (p = 0.000), there was no difference in mean AST (p = 0.939) across age. The AST:ALT ratio (AAR) progressively increased from 0.7, 0.9, and 1.1 in group A, B, and C, respectively (p = 0.000). In group C, an AAR ≥1 was found in 74 and 40 % of patients with and without advanced fibrosis. With advancing age, ALT levels progressively declined while AST levels remained stable, leading to a higher AAR. Although higher AAR is often used as a surrogate measure of advanced fibrosis, advancing age can also contribute to increased AAR. In fact, an AAR ≥1 was found in significant number of elderly patients without advanced fibrosis. Consequently, an increased AAR may be a function of decreasing ALT with age in addition to progressive fibrosis.
- Open Access
- 25 November 2007
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 1 (1) , 148
Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report
Thirty two year old Caucasian female presented 2 months post partum with fevers, cough and shortness of breath. CT scan of the chest to rule out pulmonary embolism revealed mediastinal lymphadenopathy. Biopsy of the nodes revealed classic Hodgkin's lymphoma and she received ABVD chemotherapy. She was in remission as confirmed by a PET/CT scan. Five months later she had another PET/CT scan which showed areas of hypermetabolism indicating a possible relapse. Biopsy revealed sarcoidosis. She received steroids and 18 months later remained in clinical remission. This rare case of sarcoid following classic Hodgkin's lymphoma illustrates that clinical presentation, physical exam, lab investigations and even PET/CT scans may not be able to discriminate between Hodgkin's lymphoma and sarcoidosis. Tissue biopsy and pathological diagnosis remain the gold standard.
- 25 November 2007
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 1 (1) , 148
Open AccessTissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report
Thirty two year old Caucasian female presented 2 months post partum with fevers, cough and shortness of breath. CT scan of the chest to rule out pulmonary embolism revealed mediastinal lymphadenopathy. Biopsy of the nodes revealed classic Hodgkin's lymphoma and she received ABVD chemotherapy. She was in remission as confirmed by a PET/CT scan. Five months later she had another PET/CT scan which showed areas of hypermetabolism indicating a possible relapse. Biopsy revealed sarcoidosis. She received steroids and 18 months later remained in clinical remission. This rare case of sarcoid following classic Hodgkin's lymphoma illustrates that clinical presentation, physical exam, lab investigations and even PET/CT scans may not be able to discriminate between Hodgkin's lymphoma and sarcoidosis. Tissue biopsy and pathological diagnosis remain the gold standard.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 764
Treatment of leptomeningeal carcinomatosis from breast cancer with systemically administered chemotherapy
764 Background: Leptomeningeal carcinomatosis is a rare complication of breast cancer. Standard treatment includes intrathecal methotrexate and radiation. The results of therapy are unsatisfactory and the prognosis is poor. Methods: We report two patients with breast cancer and meningeal involvement who responded to systemic chemotherapy with carboplatinum (AUC6) and docetaxel (75mg/M2. This regimen was chosen because of the preclinical synergy of these agents, proven efficacy in metastatic breast cancer, and the ability of carboplatinum to treat brain tumors. Results: Patient #1 developed isolated leptomeningeal disease 18 months after responding to neoadjuvant therapy with cyclophosphamide and doxorubicin for locally advanced breast cancer. She was originally treated with intrathecal methotrexate without response, followed by craniospinal irradiation with clinical stabilization. Eighteen months after radiation she again developed symptomatic meningeal disease along with early metastases in lung and liver. Treatment with carboplatinum and docetaxel was begun. Clinical response was prompt and MRI demonstrated improvement. Repeat CSF cytology showed only degenerating cells. She remained neurologically stable for more than 12 months. Patient #2 had previously undergone resection and cranial irradiation of cerebellar metastases from breast cancer and subsequent chemotherapy for metastatic disease with paclitaxel and trastuzumab when she developed symptomatic leptomeningeal disease. Based on the response in our previous patient, she was treated with carboplatinum and docetaxel. Trastuzumab was continued as her brain tumor overexpressed HER2/neu. Her symptoms improved, and repeat MRI and CSF exams documented response. She remains stable after 11 months of treatment. Conclusions: Systemic chemotherapy with carboplatinum and docetaxel (+trastuzumab)can be effective in the treatment of meningeal carcinomatosis from breast cancer. This regimen deserves formal study and comparison to standard treatments No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 764
Treatment of leptomeningeal carcinomatosis from breast cancer with systemically administered chemotherapy
764 Background: Leptomeningeal carcinomatosis is a rare complication of breast cancer. Standard treatment includes intrathecal methotrexate and radiation. The results of therapy are unsatisfactory and the prognosis is poor. Methods: We report two patients with breast cancer and meningeal involvement who responded to systemic chemotherapy with carboplatinum (AUC6) and docetaxel (75mg/M2. This regimen was chosen because of the preclinical synergy of these agents, proven efficacy in metastatic breast cancer, and the ability of carboplatinum to treat brain tumors. Results: Patient #1 developed isolated leptomeningeal disease 18 months after responding to neoadjuvant therapy with cyclophosphamide and doxorubicin for locally advanced breast cancer. She was originally treated with intrathecal methotrexate without response, followed by craniospinal irradiation with clinical stabilization. Eighteen months after radiation she again developed symptomatic meningeal disease along with early metastases in lung and liver. Treatment with carboplatinum and docetaxel was begun. Clinical response was prompt and MRI demonstrated improvement. Repeat CSF cytology showed only degenerating cells. She remained neurologically stable for more than 12 months. Patient #2 had previously undergone resection and cranial irradiation of cerebellar metastases from breast cancer and subsequent chemotherapy for metastatic disease with paclitaxel and trastuzumab when she developed symptomatic leptomeningeal disease. Based on the response in our previous patient, she was treated with carboplatinum and docetaxel. Trastuzumab was continued as her brain tumor overexpressed HER2/neu. Her symptoms improved, and repeat MRI and CSF exams documented response. She remains stable after 11 months of treatment. Conclusions: Systemic chemotherapy with carboplatinum and docetaxel (+trastuzumab)can be effective in the treatment of meningeal carcinomatosis from breast cancer. This regimen deserves formal study and comparison to standard treatments No significant financial relationships to disclose.